Adam Karpf, PhDUniversity of Nebraska Medical Center2018 Kirwin-Hinton Bridge Funding Award Rhno1 in High-Grade Serous Ovarian Cancer High-grade serous ovarian cancer (HGSOC) is the most common and deadly form of ovarian cancer, accounting for about 25,000 cases and 15,000 deaths in the United States every year. New and improved therapies are critically needed for HGSOC. […]
Read More
Anna deFazio, BSc (Hons), PhDUniversity of Sydney Ovulation-Related Gene Expression Signature Dysregulated in Progression to Cancer Women with a higher number of ovulations throughout their lifetime, without breaks due to pregnancy or oral contraceptives, have increased ovarian cancer risk. Dr. deFazio’s study aims to identify the genes that participate in the ovulation process in normal […]
Read More
William Foulkes, PhDMcGill University Health Center Novel target discovery in hereditary ovarian cancer by deep sequencing Ovarian cancer is an important cause of death and inherited susceptibility accounts for a substantial fraction of this cancer. Moreover, advances in knowledge of hereditary forms of cancer have led to insights into the more common, non-hereditary forms. Technological […]
Read More
Peter Kuhn, PhDUniversity of Southern California Single-cell molecular profiling of biopsies of epithelial cancer Next-generation sequencing of single cancer cells identified from the blood of ovarian cancer patients can potentially guide treatment decisions, identify recurrence early, and lead to earlier and more accurate diagnosis of the disease. Dr. Kuhn will use a “fluid biopsy” to […]
Read More
Tomer Shlomi, PhDTechnion Institute (Israel) Targeting ovarian cancer via MTAP synthetic lethality Ovarian cancer cells are genetically unstable. A deletion of the gene MTAP, which is involved in methionine metabolism, is found in 3-15% of ovarian tumors. As a result, affected ovarian cancer cells have lost a functional enzyme for metabolizing old proteins which is […]
Read More
Andrea Facciabene, PhDUniversity of Pennsylvania Tumor development influences gut flora – possible implication in early detection Early detection of ovarian cancer represents the best hope for mortality reduction and long-term disease control. Dr. Facciabene’s preliminary data indicate that developing ovarian cancer induces change in the microorganisms found in the gut, also known as the gut […]
Read More
Ilana Chefetz, PhDUniversity of Minnesota, Twin Cities Deciphering molecular mechanism of ALDH-inhibition driven necroptosis Dr. Chefetz-Menaker recently demonstrated that chemotherapy resistant ovarian cancer stem-like cells (CSC) can be identified by a protein activity known as ALDH. The expression of ALDH in CSC allows a unique opportunity to develop therapeutics specifically targeting CSC, which are thought […]
Read More
Rosana Risques, PhDUniversity of Washington 2017 Pape Family Pilot Study Award Characterization of TP53 mutations in BRCA carcinogenesis Women with inherited mutations in the BRCA1 and BRCA2 genes have a greatly increased risk of developing high-grade serous ovarian cancer (HGSOC). This type of cancer starts as a lesion in the fallopian tube, and these lesions almost always contain cells […]
Read More
David Bowtell, PhDPeter MacCallum Cancer Center2011–2013 Lester and Bernice Smith Fellow Challenge Grant Award Recipient – 2011 Circulating TP53 mutations as a biomarker of high-grade serous cancer In his proposed project, Dr. Bowtell will use the latest, most sensitive DNA sequencing techniques to study whether ovarian cancer tumors give off enough DNA into circulating blood […]
Read MoreStarting April 1, 2025, the Rivkin Center’s ovarian cancer research funding, global symposium and fundraising activities will continue under the leadership of Ovarian Cancer Research Alliance (OCRA).
